IL15 and rheumatoid arthritis: AMG714, a human monoclonal Ig G1 kappa anti IL15 Ab, has shown good response in RA.[21, 22] In a Phase II study of patients with RA who had failed at least DMARD, 54% of the patients receiving 280 mg of AMG714 achieved ACR20 compared with 38% in the placebo group.